AI labs pivot to health care as the public backlash bill comes due
With public opposition to data centers hardening into moratoriums and threatened lawsuits across the United States, frontier AI laboratories are accelerating bets on health care and drug discovery. Anthropic, preparing for a…
Key takeaways
- Frontier AI labs are accelerating investments in health care and drug discovery as public opposition to data centers hardens into moratoriums and threatened lawsuits in the US.
- Anthropic, preparing for a large IPO, has pitched investors on a deeper push into biology and medicine, with CEO Dario Amodei saying he hopes for early results in the coming months.
- The push extends across the sector: Nvidia and Eli Lilly are building a $1 billion drug discovery lab in San Francisco, and Google spinoff Isomorphic Labs raised $2.1 billion.
- Analysts describe the pivot as partly a 'hearts-and-minds play' to reframe AI as a public utility, but note actual drug discovery breakthroughs may still be years away.
- Security concerns remain, as Anthropic found its Claude Fable 5 model could give 'significant uplift' to a bad actor and imposed strict safeguards.
With public opposition to data centers hardening into moratoriums and threatened lawsuits across the United States, frontier AI laboratories are accelerating bets on health care and drug discovery. Anthropic, preparing for a large initial public offering, has been pitching investors on a deeper push into biology and medicine, the Wall Street Journal reported this month.
Chief Executive Dario Amodei wrote on X that the company is moving quickly in biology and medicine "and we hope to have incredible results in the coming years and some early glimmers in the coming months." The sector-wide push extends well beyond Anthropic. Nvidia and Eli Lilly are building a $1 billion drug discovery laboratory in San Francisco, pairing life science researchers with AI engineers. Isomorphic Labs, the drug discovery spinoff from Google, recently raised $2.1 billion to expand AI and clinical talent; it carries ongoing research collaborations with Novartis, Lilly, and Johnson & Johnson.
The capital argument underneath
Frontier labs are moving toward public markets partly to cover the cost of training new models and maintaining multi-gigawatt computing infrastructures. Diversifying into life sciences addresses both the revenue problem and the perception problem. Lloyd Price, a partner at Nelson Advisors, a digital health mergers and acquisitions firm, called it "a bit of a hearts-and-minds play," saying that real medical advances could shift public perception of AI from an environmental and security risk toward something closer to an essential public utility.
The technology is already speeding up drug development and helping clinicians analyze medical scans and diagnose conditions. It is also making health care more expensive, through software and documentation tools that more thoroughly capture the care delivered, a tension the health care pivot does not resolve.
The friction ahead
The strategy carries real risk. Public trust in large pharmaceutical companies is low, and an AI company seen as prioritizing profit over patient access could face a different kind of backlash entirely. Relations between frontier AI labs and the Trump administration remain rocky, with the administration pursuing a hands-off regulatory approach while maintaining oversight over safety and privacy. Actual drug discovery breakthroughs may still be years away.
Security concerns add their own weight. Anthropic concluded that its next-generation Claude Fable 5 model could provide "significant uplift" to a bad actor and implemented strict safeguards. More broadly, concerns persist that AI-enabled research tools could be used for nefarious purposes, including potentially enabling the development of biological weapons.
On balance, Price offered the sharpest summary of the credibility gap: "What I hear a lot is, where is the material contribution or breakthrough that's directly led to a drug discovery? It's a team sport, and AI is just a player on the field."
Related reading
Source · 來源